커넥티드 약물전달 기기 시장 예측(-2034년) - 제품 유형, 기술, 투여 경로, 치료 분야, 유통 채널, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Connected Drug Delivery Devices Market is accounted for $4.2 billion in 2026 and is expected to reach $12.8 billion by 2034, growing at a CAGR of 14.9% during the forecast period. Connected Drug Delivery Devices are smart, digitally enabled therapeutic systems that combine conventional drug administration mechanisms with integrated sensors, wireless connectivity, and data analytics capabilities. These devices transmit dosage, adherence, and physiological data in real time to healthcare providers, caregivers, and digital health platforms. By enabling remote monitoring and personalized therapy management, they improve patient compliance, clinical outcomes, and disease control across a broad spectrum of chronic and acute conditions.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases driving demand for adherence-focused delivery systems

The growing global burden of chronic illnesses such as diabetes, asthma, and autoimmune disorders has intensified the need for medication adherence solutions. Connected drug delivery devices address this challenge by transmitting real-time usage data to clinicians and caregivers, enabling timely interventions. As healthcare systems shift toward value-based care models, payers and providers are increasingly incentivizing technologies that reduce hospitalizations caused by non-adherence. The convergence of patient-centric care and digital therapeutics is accelerating adoption of these platforms across hospital and home care settings globally.

Restraint:

Stringent regulatory requirements and lengthy approval timelines

Bringing connected drug delivery devices to market requires dual compliance with both pharmaceutical and medical device regulations, including FDA 510(k) clearance or PMA approval and adherence to EU MDR standards. This dual-pathway regulatory burden significantly extends development timelines and escalates compliance costs. Additionally, integrating software-as-a-medical-device (SaMD) components introduces cybersecurity review requirements that further complicate approvals. Smaller manufacturers and emerging-market companies face disproportionate challenges in meeting these standards, limiting competitive entry and slowing innovation diffusion across global markets.

Opportunity:

Expansion of digital therapeutics and remote patient monitoring ecosystems

The rapid proliferation of digital health platforms and remote patient monitoring solutions creates significant integration opportunities for connected drug delivery devices. Pharmaceutical companies are partnering with digital health firms to build closed-loop therapy ecosystems where device data informs dose adjustments and clinical decision support. Reimbursement frameworks in North America and Europe are increasingly covering connected device programs, validating the business case for payers. The ongoing expansion of 5G infrastructure and IoT healthcare networks further enhances real-time data transmission capabilities, unlocking new therapeutic applications in oncology, neurology, and rare disease management.

Threat:

Data privacy vulnerabilities and cybersecurity risks in connected platforms

Connected drug delivery devices continuously generate and transmit sensitive patient health information, making them prime targets for cybersecurity threats. Unauthorized access to dosage records, adherence patterns, or biometric data can compromise patient privacy and expose healthcare organizations to regulatory penalties under HIPAA and GDPR. The heterogeneity of wireless communication protocols used across device ecosystems creates interoperability gaps that may introduce security vulnerabilities. As these devices become increasingly embedded within clinical workflows, ensuring end-to-end data encryption and maintaining rigorous cybersecurity governance remain critical and ongoing challenges for manufacturers and healthcare providers alike.

Covid-19 Impact:

The COVID-19 pandemic substantially accelerated demand for connected drug delivery devices by highlighting the urgent need for remote therapy management. Lockdowns and hospital capacity constraints drove patients and providers toward home-based care models, positioning these devices as essential tools for chronic disease management outside clinical settings. Pandemic-driven regulatory flexibilities also expedited digital health approvals, bringing new connected solutions to market faster. As healthcare systems worldwide rebuild with resilience and digitization as core priorities, the momentum gained during the pandemic continues to fuel sustained investment and adoption in connected drug delivery ecosystems.

The integrated connected devices segment is expected to be the largest during the forecast period

The integrated connected devices segment is expected to account for the largest market share during the forecast period, owing to its comprehensive design that combines drug delivery mechanisms with embedded connectivity and sensing capabilities in a single platform. Connected inhalers and connected injectable devices are experiencing strong adoption driven by growing respiratory and metabolic disease prevalence. Healthcare providers favor integrated solutions that eliminate the need for add-on hardware and simplify patient onboarding. Pharmaceutical companies are increasingly launching combination products that pair biologics and specialty drugs with proprietary connected delivery platforms, reinforcing the dominance of this segment.

The smart packaging & monitoring devices segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the smart packaging & monitoring devices segment is predicted to witness the highest growth rate, driven by escalating demand for cost-effective adherence monitoring solutions across oral drug therapies. Smart pill bottles and smart blister packs are gaining rapid traction among pharmaceutical companies conducting clinical trials and managing complex multi-drug regimens in elderly populations. These devices offer a non-invasive adherence tracking approach compatible with existing pharmaceutical supply chains. Favorable reimbursement trends and growing pharmacy digitization initiatives in North America and Europe are further propelling adoption of smart packaging technologies.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by the region's advanced healthcare infrastructure, high chronic disease burden, and robust digital health ecosystem. The United States benefits from a well-established reimbursement environment for connected health technologies, alongside a dense network of pharmaceutical innovators and medtech companies driving product development. Strong patient awareness of digital therapeutics, combined with supportive regulatory initiatives from the FDA toward software-enabled medical devices, reinforces the region's leadership position in the global connected drug delivery devices landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly expanding healthcare infrastructure, increasing smartphone penetration, and growing awareness of chronic disease management technologies. Countries such as China, India, Japan, and South Korea are investing heavily in digital health ecosystems and connected medical device innovation. Rising middle-class healthcare spending and government-led digital transformation initiatives are creating favorable conditions for market entry. The region's large patient population with unmet adherence management needs presents substantial commercialization opportunities for global and regional connected drug delivery device manufacturers.

Key players in the market

Some of the key players in Connected Drug Delivery Devices Market include Medtronic plc, Becton Dickinson and Company, Ypsomed AG, West Pharmaceutical Services Inc., Phillips-Medisize Corporation, Insulet Corporation, Tandem Diabetes Care Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., BIOCORP, Adherium Limited, Propeller Health, Gerresheimer AG, and ResMed Inc.

Key Developments:

In March 2026, Medtronic announced the global launch of its next-generation connected insulin delivery platform integrated with continuous glucose monitoring capabilities. The system enables automated dose adjustment recommendations transmitted directly to patient smartphones and clinician dashboards, targeting improved glycemic outcomes for Type 1 and Type 2 diabetes patients in both hospital and home care settings.

In January 2026, Becton Dickinson and Company announced a strategic collaboration with a leading digital therapeutics company to co-develop a connected injectable drug delivery platform incorporating adherence tracking and real-time patient reporting features. The partnership aims to accelerate the commercialization of combination biologics-device products targeting autoimmune disease and oncology therapy segments.

Product Types Covered:

• Connected Sensors
• Integrated Connected Devices
• Smart Packaging & Monitoring Devices

Technologies Covered:

• Bluetooth
• Near Field Communication (NFC)
• Wi-Fi
• Cellular / LPWAN Connectivity
• Cloud-Based Platforms
• Other Technologies

Routes of Administration Covered:

• Injectable / Parenteral
• Inhalational
• Oral Drug Delivery
• Transdermal Delivery

Therapeutic Areas Covered:

• Diabetes Management
• Respiratory Diseases
• Autoimmune Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Oncology
• Hormonal Disorders
• Other Chronic Diseases

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct Sales

End Users Covered:

• Hospitals
• Clinics & Specialty Centers
• Home Care Settings
• Ambulatory Care Centers
• Pharmaceutical & Biotech Companies
• Patients & Caregivers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Connected Drug Delivery Devices Market, By Product Type

• 5.1 Connected Sensors
  • 5.1.1 Connected Inhaler Sensors
  • 5.1.2 Connectable Injection Sensors
  • 5.1.3 Add-on Smart Caps & Modules
• 5.2 Integrated Connected Devices
  • 5.2.1 Connected Inhalers
  • 5.2.2 Connected Injectable Devices
• 5.3 Smart Packaging & Monitoring Devices
  • 5.3.1 Smart Pill Bottles
  • 5.3.2 Smart Blister Packs

6 Global Connected Drug Delivery Devices Market, By Technology

• 6.1 Bluetooth
• 6.2 Near Field Communication (NFC)
• 6.3 Wi-Fi
• 6.4 Cellular / LPWAN Connectivity
• 6.5 Cloud-Based Platforms
• 6.6 Other Technologies

7 Global Connected Drug Delivery Devices Market, By Route of Administration

• 7.1 Injectable / Parenteral
• 7.2 Inhalational
• 7.3 Oral Drug Delivery
• 7.4 Transdermal Delivery

8 Global Connected Drug Delivery Devices Market, By Therapeutic Area

• 8.1 Diabetes Management
• 8.2 Respiratory Diseases
• 8.3 Autoimmune Diseases
• 8.4 Cardiovascular Diseases
• 8.5 Neurological Disorders
• 8.6 Oncology
• 8.7 Hormonal Disorders
• 8.8 Other Chronic Diseases

9 Global Connected Drug Delivery Devices Market, By Distribution Channel

• 9.1 Hospital Pharmacies
• 9.2 Retail Pharmacies
• 9.3 Online Pharmacies
• 9.4 Direct Sales

10 Global Connected Drug Delivery Devices Market, By End User

• 10.1 Hospitals
• 10.2 Clinics & Specialty Centers
• 10.3 Home Care Settings
• 10.4 Ambulatory Care Centers
• 10.5 Pharmaceutical & Biotech Companies
• 10.6 Patients & Caregivers

11 Global Connected Drug Delivery Devices Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Medtronic plc
• 14.2 Becton, Dickinson and Company
• 14.3 Ypsomed AG
• 14.4 West Pharmaceutical Services, Inc.
• 14.5 Phillips-Medisize Corporation
• 14.6 Insulet Corporation
• 14.7 Tandem Diabetes Care, Inc.
• 14.8 Novo Nordisk A/S
• 14.9 Teva Pharmaceutical Industries Ltd.
• 14.10 AptarGroup, Inc.
• 14.11 BIOCORP
• 14.12 Adherium Limited
• 14.13 Propeller Health
• 14.14 Gerresheimer AG
• 14.15 ResMed Inc.